-
公开(公告)号:US20240190809A1
公开(公告)日:2024-06-13
申请号:US18560543
申请日:2022-05-11
Applicant: Awakn LS Europe Holdings Limited
Inventor: David Nutt , Alan Borthwick
IPC: C07C229/46 , A61K9/00 , A61K9/10 , A61K9/20 , A61K9/48 , A61K45/06 , A61K47/10 , A61K47/12 , A61K47/26 , A61K47/32 , A61K47/36 , A61K47/38 , A61K47/44 , A61P25/00 , A61P25/30 , A61P25/32 , C07C229/50 , C07D305/14 , C07D307/77 , C07D311/78 , C07D313/06 , C07D313/20
CPC classification number: C07C229/46 , A61K9/0014 , A61K9/0019 , A61K9/006 , A61K9/10 , A61K9/2013 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/4858 , A61K9/4866 , A61K45/06 , A61K47/10 , A61K47/12 , A61K47/26 , A61K47/32 , A61K47/36 , A61K47/38 , A61K47/44 , A61P25/00 , A61P25/30 , A61P25/32 , C07C229/50 , C07D305/14 , C07D307/77 , C07D311/78 , C07D313/06 , C07D313/20
Abstract: The present invention discloses therapeutic compounds of the aminoindane class, including certain short-acting ester and lactone derivatives, and pharmaceutical compositions made therewith, as well as methods of their use in the treatment of alcohol and other substance use disorders, behavioral addictions, and CNS and mental health disorders, and for the improvement of mental health and psychological functioning.
-
公开(公告)号:US20210007363A1
公开(公告)日:2021-01-14
申请号:US17040227
申请日:2019-03-21
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD
Inventor: Asaph AHARONI , Elisa KORENBLUM
IPC: A01N63/38 , C07D305/14 , C07J17/00 , A01N63/20 , A01G29/00
Abstract: Provided is a plant exudate, methods for obtaining a plant exudate by inducing the plant to secrete an exudate and systems for the collection of a plant exudate which include: one or more plant container including at least two discrete compartments each configured to accommodate a split root of a plant, the compartments being a root stimulating compartment including one or more input being in fluid communication with at least a source of a plant root stimulant, and a root exudate harvesting compartment, and a root exudate collection compartment in fluid communication with the root exudate harvesting compartment.
-
公开(公告)号:US20200331876A1
公开(公告)日:2020-10-22
申请号:US16753591
申请日:2018-10-04
Applicant: Novomer, Inc.
Inventor: Oleg Kulikov , Sadesh H. Sookraj , Utpal Mahendra Vakil , Matthew Goodrich
IPC: C07D305/12 , C07D305/08 , C07D307/20 , C07D407/12 , C07D305/14 , C08G18/09 , C08L75/04
Abstract: The present invention is directed to processes for producing isocyanates and isocyanate derivatives from epoxide and carbon monoxide reagents. In preferred embodiments, the processes include a step for providing carbonylation of an epoxide reagent with a carbon monoxide reagent to produce a beta-lactone intermediate. In certain preferred embodiments, further carbonylation of a beta-lactone intermediate produces a succinic anhydride intermediate. The processes of the present invention include steps for rearranging beta-lactone intermediates and/or succinic anhydride intermediates to produce isocyanate products and/or isocyanate derivatives. In certain preferred embodiments, the isocyanate products may be copolymerized with polyol oligomers to provide polyurethane products.
-
公开(公告)号:US10590099B1
公开(公告)日:2020-03-17
申请号:US15674453
申请日:2017-08-10
Applicant: Novomer, Inc.
Inventor: Sadesh H. Sookraj
IPC: C07D305/12 , C07D305/14 , C07D407/12 , C07D407/06 , B01J31/18 , B01J37/08 , B01J31/20 , B01J37/04 , B01J37/02
Abstract: The present invention is directed to processes from producing beta-lactone and beta-lactone derivatives using heterogenous catalysts. In preferred embodiments of the present invention, the processes comprise the steps: passing a feed stream comprising an epoxide reagent and a carbon monoxide reagent to a reaction zone; contacting the epoxide reagent and the carbon monoxide reagent with a heterogenous catalyst to produce a beta-lactone product in the reaction zone; and removing the beta-lactone product from the reaction zone. In preferred embodiments, the heterogenous catalyst comprises a solid support containing a cationic Lewis acid functional group and a metal carbonyl compound comprising at least one of anionic metal carbonyl compound or a neutral metal carbonyl compound. In certain preferred embodiments, the epoxide reagent and carbon monoxide reagent have a biobased content.
-
公开(公告)号:US20190142784A1
公开(公告)日:2019-05-16
申请号:US16247425
申请日:2019-01-14
Applicant: Tapestry Pharmaceuticals, Inc.
Inventor: Jan Zygmunt , James Ferrara , James D. McChesney
IPC: A61K31/337 , C07D409/12 , A61K31/357 , C07D305/14 , C07D493/08
Abstract: Provided herein are compounds, compositions containing the compounds, and methods for the treatment of cancer in a cancer patient. In particular, the compounds are made by a process comprising treating a first compound represented by either Formula G′ or Formula M′: with a second compound of generalized formula R8R9C(OCH3)2 and an acid selected from the group consisting of camphor sulfonic acid (CSA), p-toluene sulfonic acid (PTSA), hydrochloric acid (HCl) and acetic acid (AcOH), wherein R1 and R2 are each selected from H, an alkyl group, an olefinic group, an aromatic group, an O-alkyl group, an O-olefinic group, or an O-aromatic group; R7 is an alkyl group, an olefinic group, or an aromatic group; P1 is a hydroxyl protecting group; P5 is H or an acid labile protecting group at the 7-O position; R8 is H, alkyl group, olefinic or aromatic group; and R9 is: H, alkyl group, olefinic or aromatic or is as defined in the specification.
-
公开(公告)号:US10253007B2
公开(公告)日:2019-04-09
申请号:US15038264
申请日:2014-11-21
Applicant: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
Inventor: Wei Zhou , Yunrong Jing , Yongfeng Wang , Guocheng Wang
IPC: A61K31/337 , C07D305/14 , C07D405/12 , C07C271/22 , C07C233/87
Abstract: The present invention provides taxanes compounds with a formula (I) or formula (II) structure, a method for preparing the compounds, as well as the use of the compositions containing the compounds, pharmaceutically acceptable salts and solvates thereof as active ingredients in manufacturing oral antitumor medicaments, In formula (I), R1 is —COR6, —COOR6 or —CONR7aR7b; R2 is a C1-C6 alkyl, a C1-C6 alkenyl, a substituted hydrocarbon group, a heterocyclic group, an aromatic group or a substituted aromatic group; R3 is —OR6, —OCOOR6, —OCOSR6 or —OCONR7aR7b; R4 is —OR6, —OCOOR6, —OCOSR6, —OCONR7aR7b or H; wherein, R6 is a C1-C6 alkyl, a C1-C6 alkenyl, a C1-C6 alkynyl, a substituted hydrocarbon group, an aromatic group or a heterocyclic group; R7a and R7b are respectively hydrogen, a hydrocarbon group, a substituted hydrocarbon group or a heterocyclic group. In formula (II), R1 is —COR6 or —COOR6; R2 is an aromatic group; R3 is —OR6; wherein, R6 is a C1-C6 alkyl, a C1-C6 alkenyl, a C1-C6 alkynyl, a substituted hydrocarbon group, an aromatic group or a heterocyclic group.
-
公开(公告)号:US10172957B2
公开(公告)日:2019-01-08
申请号:US15675399
申请日:2017-08-11
Applicant: Arbor Therapeutics, LLC
IPC: A61K47/54 , C07D305/14 , C07D317/24 , C07D407/12 , C07D487/04 , C07D491/14 , C07D493/06 , C07D493/08 , C07D519/00 , A61K31/337 , A61K31/357
Abstract: The present application discloses an acid labile lipophilic molecular conjugate of cancer chemotherapeutic agents and methods for reducing or substantially eliminating the side effects of chemotherapy associated with the administration of a cancer chemotherapeutic agent to a patient in need thereof.
-
公开(公告)号:US20180222915A1
公开(公告)日:2018-08-09
申请号:US15945285
申请日:2018-04-04
Inventor: Cassandra E. Callmann , Matthew P. Thompson , Nathan C. Gianneschi , Clare L. M. LeGuyader , Paul A. Bertin
IPC: C07D491/044 , A61K9/00 , A61K47/54 , C07H15/252 , C07D491/22 , C07D305/14 , C07D475/08
CPC classification number: C07D491/044 , A61K9/0019 , A61K47/42 , A61K47/542 , C07D305/14 , C07D475/08 , C07D491/22 , C07H15/252
Abstract: The present disclosure generally provides compounds useful for treating cancer. In some aspects, the disclosure provides small-molecule cytotoxins that are chemically modified to include one or more moieties that include hydrophobic portions. In some embodiments, the disclosure provides small-molecule cytotoxins that are chemically modified with fatty acid-containing moieties. In some aspects, the disclosure provides compositions, such as pharmaceutical compositions, that include such modified small-molecule cytotoxins and a protein. In some embodiments, the protein is albumin or an albumin mimetic. Further, the disclosure provides various uses of these compounds and compositions.
-
公开(公告)号:US20180221279A1
公开(公告)日:2018-08-09
申请号:US15948716
申请日:2018-04-09
Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
Inventor: Pieter Cullis , Marcel Bally , Marco Ciufolini , Norbert Maurer , Igor Jigaltsev
IPC: A61K9/127 , A61K47/54 , C07J41/00 , C07J43/00 , A61K31/573 , A61K31/706 , C07K7/64 , C07D305/14 , C07D405/12 , C07D498/14 , A61K31/5377 , A61K31/4525 , A61K31/496 , A61K31/337 , C07H17/04
CPC classification number: A61K9/127 , A61K9/1278 , A61K31/337 , A61K31/4525 , A61K31/496 , A61K31/5377 , A61K31/573 , A61K31/706 , A61K47/542 , A61P29/00 , C07D305/14 , C07D405/12 , C07D498/14 , C07H17/04 , C07J41/005 , C07J43/003 , C07K7/645
Abstract: Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags.
-
公开(公告)号:US09968554B2
公开(公告)日:2018-05-15
申请号:US14302537
申请日:2014-06-12
Applicant: The University of British Columbia
Inventor: Pieter Cullis , Marcel Bally , Marco Ciufolini , Norbert Maurer , Igor Jigaltsev
IPC: A61K9/127 , A61K31/337 , A61K31/496 , A61K31/4525 , A61K31/5377 , A61K31/573 , A61K31/706 , C07D305/14 , C07D405/12 , C07D498/14 , C07H17/04 , C07J41/00 , C07J43/00 , C07K7/64 , A61K47/54
CPC classification number: A61K9/127 , A61K9/1278 , A61K31/337 , A61K31/4525 , A61K31/496 , A61K31/5377 , A61K31/573 , A61K31/706 , A61K47/542 , C07D305/14 , C07D405/12 , C07D498/14 , C07H17/04 , C07J41/005 , C07J43/003 , C07K7/645
Abstract: Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags.
-
-
-
-
-
-
-
-
-